BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McGarry ME, Neuhaus JM, Nielson DW, Ly NP. Regional variations in longitudinal pulmonary function: A comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States. Pediatr Pulmonol 2019;54:1382-90. [PMID: 31144477 DOI: 10.1002/ppul.24377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Dongarwar D, Garcia BY, Miller K, Salihu HM. Assessment of hospitalization rates, factors associated with hospitalization and in-patient mortality in pediatric patients with cystic fibrosis. J Natl Med Assoc 2021:S0027-9684(21)00190-5. [PMID: 34479733 DOI: 10.1016/j.jnma.2021.08.038] [Reference Citation Analysis]
2 McGarry ME, Williams WA 2nd, McColley SA. The demographics of adverse outcomes in cystic fibrosis. Pediatr Pulmonol 2019;54 Suppl 3:S74-83. [PMID: 31715087 DOI: 10.1002/ppul.24434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Savant AP, McColley SA. Cystic fibrosis year in review 2019: Section 2 pulmonary disease and infections. Pediatr Pulmonol 2020. [PMID: 32970381 DOI: 10.1002/ppul.25091] [Reference Citation Analysis]
4 McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol 2021;56:1496-503. [PMID: 33470563 DOI: 10.1002/ppul.25285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
5 Albon D, Van Citters AD, Ong T, Dieni O, Dowd C, Willis A, Sabadosa KA, Scalia P, Reno K, Oates GR, Schechter MS. Telehealth use in cystic fibrosis during COVID-19: Association with race, ethnicity, and socioeconomic factors. J Cyst Fibros 2021;20 Suppl 3:49-54. [PMID: 34930543 DOI: 10.1016/j.jcf.2021.09.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
6 McColley SA, Martiniano SL, Ren CL, Sontag MK, Rychlik K, Balmert L, Elbert A, Wu R, Farrell PM. Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening. J Cyst Fibros 2022:S1569-1993(22)00628-2. [PMID: 35871976 DOI: 10.1016/j.jcf.2022.07.010] [Reference Citation Analysis]
7 Mcgarry ME, Gibb ER, Oates GR, Schechter MS. Left Behind: The Potential Impact of CFTR Modulators on Racial and Ethnic Disparities in Cystic Fibrosis. Paediatric Respiratory Reviews 2021. [DOI: 10.1016/j.prrv.2021.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zampoli M, Verstraete J, Frauendorf M, Kassanjee R, Workman L, Morrow BM, Zar HJ. Cystic fibrosis in South Africa: spectrum of disease and determinants of outcome. ERJ Open Res 2021;7:00856-2020. [PMID: 34350279 DOI: 10.1183/23120541.00856-2020] [Reference Citation Analysis]
9 Januska MN, Marx L, Walker PA, Berdella MN, Langfelder-Schwind E. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. J Genet Couns 2020;29:607-15. [PMID: 32227567 DOI: 10.1002/jgc4.1271] [Reference Citation Analysis]
10 McGarry ME, Huang CY, Nielson DW, Ly NP. Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States. J Cyst Fibros 2021;20:424-31. [PMID: 33162303 DOI: 10.1016/j.jcf.2020.10.002] [Reference Citation Analysis]
11 Oates GR, Schechter MS. Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies. Expert Rev Respir Med 2022;:1-14. [PMID: 35705523 DOI: 10.1080/17476348.2022.2090928] [Reference Citation Analysis]